Trial reportThe British journal of ophthalmology2008
Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial.
Trial report in The British journal of ophthalmology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 130 citations in OpenAlex.
- Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.The Cochrane database of systematic reviews · 2019Pooled it
- Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.The Cochrane database of systematic reviews · 2014Pooled it
- A retrospective, pooled data analysis of the safety of pegaptanib sodium in the treatment of age-related macular degeneration in subjects with or without diabetes mellitus.BMC ophthalmology · 2012Trial
- Pegaptanib sodium as maintenance therapy in neovascular age-related macular degeneration: the LEVEL study.The British journal of ophthalmology · 2010Trial
- RNA dysfunction in age-related macular degeneration: the role of U1 snRNP complex and neurodegenerative diseases.International journal of retina and vitreous · 2025Review
- The 20th Anniversary of Pegaptanib (MacugenTM), the First Approved Aptamer Medicine: History, Recent Advances and Future Prospects of Aptamers in Therapy.Pharmaceutics · 2025Review
- Surgical Management of Diabetic Macular Edema.Current diabetes reports · 2023Review
- Novel Nanotherapeutics for Cancer Immunotherapy by PD-L1-Aptamer-Functionalized and Fexofenadine-Loaded Albumin Nanoparticles.Molecules (Basel, Switzerland) · 2023Article
- Progress on the application of growth factor-related drugs in ophthalmology.Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2022Review
- Objective evaluation of changes in lens clarity after repeated injections of ranibizumab in patients with neovascular age-related macular degeneration.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2022Article
- Association of Intravitreal Anti-Vascular Endothelial Growth Factor Therapy With Risk of Stroke, Myocardial Infarction, and Death in Patients With Exudative Age-Related Macular Degeneration.JAMA ophthalmology · 2019Article
- Article
- A modified treat-and-extend regimen of aflibercept for treatment-naïve patients with neovascular age-related macular degeneration.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2017Article
- Non-responsiveness to intravitreal aflibercept treatment in neovascular age-related macular degeneration: implications of serous pigment epithelial detachment.Scientific reports · 2016Article
- Study of the Acute Effects of Povidone-Iodine on Conjunctival Bacterial Flora.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2015Article
- Intravitreal pegaptanib for the treatment of ischemic diabetic macular edema.Clinical ophthalmology (Auckland, N.Z.) · 2015Article
- Retinal tears and rhegmatogenous retinal detachment after intravitreal injections: its prevalence and case reports.Digital journal of ophthalmology : DJO · 2015Article
- Aflibercept: a review of its use in the treatment of choroidal neovascularization due to age-related macular degeneration.Clinical ophthalmology (Auckland, N.Z.) · 2015Review
- Therapeutic Modalities of Exudative Age-related Macular Degeneration.Medical archives (Sarajevo, Bosnia and Herzegovina) · 2014Review
- A review of anti-VEGF agents for proliferative diabetic retinopathy.Eye (London, England) · 2014Review
Corrections and comments
- Commented on by
Authors and funding
9 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsTo evaluate the safety of up to 3 years of pegaptanib sodium therapy in the treatment of neovascular age-related macular degeneration (NV-AMD).
methodsTwo concurrent, prospective, multicentre, double-masked studies randomised subjects with all angiographic lesion compositions of NV-AMD to receive intravitreous pegaptanib sodium (0.3, 1 and 3 mg) or sham injections every 6 weeks for 54 weeks. Those initially assigned to pegaptanib were rerandomised to continue or discontinue therapy for 48 more weeks; sham-treated subjects continued sham, discontinued or received pegaptanib. At 102 weeks, subjects receiving pegaptanib 0.3 mg or 1 mg in years 1 or 2 continued; those receiving pegaptanib 3 mg or who did not receive treatment in years 1 and 2 were rerandomised to 0.3 mg or 1 mg for year 3.
resultsAs in years 1 and 2, pegaptanib was well tolerated in year 3. Adverse events were mainly ocular in nature, mild, transient and injection-related. Serious adverse events were rare. No evidence of systemic safety signals attributed to vascular endothelial growth factor inhibition arose in year 3. There were no findings in relation to vital signs or electrocardiogram results suggesting a relationship to pegaptanib treatment.
conclusionThe 3-year safety profile of pegaptanib sodium was favourable in patients with NV-AMD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.